Beta Bionics (NASDAQ:BBNX – Get Free Report) and NexGel (NASDAQ:NXGL – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.
Volatility and Risk
Beta Bionics has a beta of 3.44, suggesting that its stock price is 244% more volatile than the S&P 500. Comparatively, NexGel has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.
Earnings and Valuation
This table compares Beta Bionics and NexGel”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beta Bionics | $100.25 million | 9.15 | -$73.20 million | ($1.84) | -9.17 |
| NexGel | $12.07 million | 0.17 | -$3.00 million | ($14.20) | -0.29 |
NexGel has lower revenue, but higher earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than NexGel, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
2.2% of NexGel shares are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 19.8% of NexGel shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings and target prices for Beta Bionics and NexGel, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beta Bionics | 1 | 4 | 9 | 1 | 2.67 |
| NexGel | 1 | 2 | 0 | 0 | 1.67 |
Beta Bionics presently has a consensus target price of $23.69, indicating a potential upside of 40.36%. NexGel has a consensus target price of $40.00, indicating a potential upside of 862.70%. Given NexGel’s higher probable upside, analysts clearly believe NexGel is more favorable than Beta Bionics.
Profitability
This table compares Beta Bionics and NexGel’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beta Bionics | -65.31% | -27.33% | -24.28% |
| NexGel | -51.26% | -121.18% | -41.15% |
Summary
Beta Bionics beats NexGel on 9 of the 15 factors compared between the two stocks.
About Beta Bionics
Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user’s body weight and adjusts insulin delivery based on glucose readings.
About NexGel
NexGel, Inc. (NASDAQ:NXGL) develops and manufactures high-water-content hydrogel products for medical, consumer and other specialized applications. The company uses proprietary formulations and electron-beam processing to produce flexible, skin-compatible products designed to retain moisture and provide cooling, cushioning or conductive properties. Its product applications include wound care, burn and surgical care, pain management, medical diagnostics and personal wellness. NexGel supplies hydrogel sheets, patches and related components used in products such as wound dressings, therapeutic pads and medical electrodes.
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
